Access to medicines in resource-limited settings: The end of a golden decade?

Global Advances In Health and Medicine

Volumn 1, Issue 1, 2012, Pages 52-59

  von Schoen Angerer, Tido ^a   Ford, Nathan ^a,b   Arkinstall, James ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Access; Doha declaration; GFATM; Global fund to fight AIDS; Global health; HIV; HIV AIDS; Innovation; Intellectual property; Malaria; Medicines; Policy; Product development partnerships; Public health; Resourcelimited; TB; Tuberculosis; Tuberculosis and malaria; WHO; World health organization

Indexed keywords

ANTIRETROVIRUS AGENT; ARTEMISININ; BEDAQUILINE; CHLOROQUINE; DELAMANID; ETRAVIRINE; PYRIMETHAMINE PLUS SULFADOXINE; RALTEGRAVIR; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE SEVERITY; DRUG COST; DRUG INDUSTRY; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; POLITICS; PRIORITY JOURNAL; PUBLIC HEALTH; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84876851475     PISSN: 2164957X     EISSN: 21649561     Source Type: Journal    
DOI: 10.7453/gahmj.2012.1.1.011     Document Type: Article

References (59)

1. Global health in 2012: development to sustainability. Lancet. 2012 Jan 21;379(9812):193.
2. United Nations General Assembly. United Nations Millennium Declaration. Resolution A/RES/55/2. New York: United Nations General Assembly, September 18, 2000. Cited February 2, 2012. Available from: http://www.un.org/millennium/declaration/ares552e.pdf.
3. Sachs J. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. World Health Organization. Geneva.
4. Das P, Samarasekera U. The Commission on Macroeconomics and Health: 10 years on. Lancet. 2011; 378(9807): 1907-8.
5. Annan K. Ten-year fight for world health A war chest Le Monde Diplomatique January 2012 http://mondediplocom/2012/01/16warchest [accessed 26 January 2012].
6. Declaration on the TRIPS agreement and public health: adopted on 14 November 2001. World Trade Organization. http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm. Accessed January 28, 2012.
7. Ridley RG, Lob-Levyt J, Sachs J, Johns D, Evans T, Bale HE, et al. Round table. A role for public-private partnerships in controlling neglected diseases? Bull World Health Organ. 2001; 79(8): 771-7.
8. Moran M RA, Guzman J, Diaz J, Garrison C. The new landscape of neglected disease drug development. London School of Economics and The Wellcome Trust. London, 2005.
9. von Schoen Angerer T, Wilson D, Ford N, Kasper T. Access and activism: the ethics of providing antiretroviral therapy in developing countries. Aids. 2001;15 Suppl 5: S81-90.
10. Hoen E, Berger J, Calmy A, Moon S. Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc. 2011 Mar 27;14:15.
11. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002 Jun 22;359(9324):2188-94.
12. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9.
13. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: Progress report 2011. Geneva: World Health Organization; 2011. Cited January 26, 2012. Available from: http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf.
14. Médecins Sans Frontières. Untangling the web of anti-retroviral price reduction. 14th ed. Geneva: Médecins Sans Frontières; 2011.
15. Ford N, Calmy A, Mills EJ. The first decade of antiretroviral therapy in Africa. Global Health. 2011 Sep 29;7:33.
16. The Global Fund. Our strategy: the global fund strategy 2012-2016: investing for impact. http://www.theglobalfund.org/en/about/strategy/. Accessed January 28, 2012.
17. Remarks by the president on world AIDS day [news release]. Washington, DC: The White House Office of the Press Secretary; December 1, 2011. http://www.whitehouse. gov/the-press-office/2011/12/01/remarks-president-world-aids-day. Accessed January 28, 2012.
18. Hurst A. The global fund adopts new strategy to save 10 million lives by 2016. November 23, 2011. http://www.theglobalfund.org/en/mediacenter/pressreleases/2011-11-23_The_Global_Fund_adopts_new_strategy_to_save_10_million_ lives_by_2016/. Accessed January 28, 2012.
19. United Nations General Assembly. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS. Resolution A/RES/65/277. New York: United Nations General Assembly; 2011
20. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.
21. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet. 2011 Dec 17;378(9809):e23-5.
22. Schwartländer B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011 Jun 11;377(9782):2031-41.
23. Waning B, Diedrichsen E, Moon S. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc. 2010 Sep 14;13:35.
24. All Parliamentary Group on AIDS. The treatment timebomb. London: All Parliamentary Group on AIDS; 2009.
25. World Health Organization. Global tuberculosis control 2011. Geneva: World Health Organization; 2011.
26. Keshavjee S, Farmer PE. Picking up the pace-scale-up of MDR tuberculosis treatment programs. N Engl J Med. 2010 Nov 4;363(19):1781-4.
27. Farmer P. Infections and inequalities: the modern plagues. Berkeley: University of California Press; 1999.
28. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis-critical steps for prevention and control. N Engl J Med. 2010 Sep 9;363(11):1050-8.
29. Médecins Sans Frontières. DR-TB drugs under the microscope: the sources and prices for drug resistant tuberculosis medicines. Geneva: Médecins Sans Frontières, International Union Against TB and Lung Disease; 2011.
30. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med. 2 2011 Nov;8(11):e1001120.
31. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009 Mar;9(3):153-61.
32. Shin S, Furin J, Bayona J, Mate K, Kim JY, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med. 2004 Oct;59(7):1529-39.
33. Malla P, Kanitz EE, Akhtar M, F et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One. 2009 Dec 23;4(12):e8313.
34. World Health Organization. World malaria report 2011. Geneva: World Health O4ganization; 2011.
35. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012 Feb 4;379(9814):413-31.
36. Roll Back Malaria Partnership. Eliminating malaria: learning from the past, looking ahead. Geneva: World Health Organization; 2011.
37. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011 Oct 11;17(10):1217-20.
38. Roll Back Malaria Partnership, World Health Organization. The use of antimalarial drugs: report of a WHO informal consultation: 13-17 November 2000. Geneva: Roll Back Malaria/World Health Organization; 2001.
39. Guthmann JP, Checchi F, van den Broek I, et al. Assessing antimalarial efficacy in a time of change to artemisinin-based combination therapies: the role of Médecins Sans Frontières. PLoS Med. 2008 Aug 5;5(8):e169.
40. Moon S, Pérez Casas C, Kindermans JM, de Smet M, von Schoen-Angerer T. Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med. 2009 Jul 21;6(7):e1000106.
41. Barbacka K, Baer-Dubowska W. Searching for artemisinin production improvement in plants and microorganisms. Curr Pharm Biotechnol. 2011 Nov 1;12(11):1743-51.
42. Matowe L, Adeyi O. The quest for universal access to effective malaria treatment: how can the AMFm contribute? Malar J. 2010 Oct 8;9:274.
43. Roll Back Malaria Partnership, World Health Organization. RBM-WHO round table on ACT supply. Geneva: Roll Back Malaria Partnership, World Health Organization; 2011.
44. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an openlabel, randomised trial. Lancet. 2010 Nov 13;376(9753):1647-57.
45. Ford NP, de Smet M, Kolappa K, White NJ. Responding to the evidence for the management of severe malaria. Trop Med Int Health. 2011 Sep;16(9):1085-6.
46. World Health Organization. Universal access to malaria diagnostic testing: an operational manual 2011. Geneva: World Health Organization; 2011.
47. Balabanova D, McKee M, Mills A, Walt G, Haines A. What can global health institutions do to help strengthen health systems in low income countries? Health Res Policy Syst. 2010 Jun 29;8:22.
48. Cometto G, Ooms G, Starrs A, Zeitz P. Towards a global fund for the health MDGs. Lancet. 2009 Oct 3;374(9696):1146.
49. Beaglehole R, Bonita R, Alleyne G, et al. UN High-Level Meeting on Non-Communicable Diseases: addressing four questions. Lancet. 2011 Jul 30;378(9789):449-55.
50. Simon C, de Lemos G. [UNITAID: an innovative and collective financing system for the fight against malaria, AIDS and tuberculosis]. Med Trop (Mars). 2006 Dec;66(6):583-4. French.
51. McColl K. Bill Gates is to urge G20 nations to adopt a financial transaction tax to fund development. BMJ. 2011 Oct 26;343:d6963.
52. Ford N, Wilson D, Costa Chaves G, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand. AIDS. 2007 Jul;21 Suppl 4:S21-9.
53. How the Trans-Pacific Partnership Agreement threatens access to medicines. Doctors Without Borders/Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines TPP Issue Brief, September 2011. Cited January 26, 2012. Available from: http://www.doctorswithoutborders.org/press/2011/MSF-TPPIssue-Brief.pdf.
54. Moon S, Jambert E, Childs M, von Schoen-Angerer T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health. 2011 Oct 12;7(1):39.
55. Moran M, Guzamn J, Abela-Oversteegen L, et al. Neglected disease research and development: is innovation under threat? Sydney: Policy Cures; 2011. Cited January 26, 2012. Available from: http://policycures.org/downloads/g-finder_2011.pdf.
56. 't Hoen E. Report of the Commission on Intellectual Property Rights, Innovation and Public Health: a call to governments. Bull World Health Organ. 2006 May;84(5):421-3.
57. Sixty-first World Health Assembly. Global strategy and plan of action for public health, innovation and intellectual property. Resolution A61.21. Geneva: World Health Assembly; 2008.
58. Love J, Hubbard T. Prizes for innovation of new medicines and vaccines. Ann Health Law. 2009;18(2):155-86, 8 p. preceding i.
59. World Health Organization Consultative Expert Working Group on Research and Development. Report of the third meeting of the consultative expert working group on research and development: financing and coordination. Geneva: World Health Organization; 2011.